Accelerated Biosciences ("Accelerated Bio"), in partnership with Pluristyx, proudly announces the successful creation of clinical grade induced pluripotent stem cell (iPSC) lines using a novel starting material.

This groundbreaking achievement utilizes Accelerated Bio’s pre-implantation human trophoblast stem cells (hTSC) as the foundational material. hTSCs are ethically sourced, pre-implantation, low-passage (“young”) cells with unique plasticity and high expansion capacity.

Starting with hTSCs, Pluristyx® reprogrammed two separate donor stocks of GMP hTSCs with their proprietary mRNA reprogramming technology to generate multiple iPSC clones for use as seed stock for GMP master cell banks.

Benjamin Fryer, CEO of Pluristyx, expressed his enthusiasm about the partnership: "Our partnership with Accelerated Bio aligns perfectly with our mission to make iPSCs more accessible to the industry. By leveraging our advanced reprogramming technology, we aim to diversify the iPSC market, offering more choices for cell therapy development."

Yuta Lee, CEO of Accelerated Bio, emphasized the advanced capabilities of the hTSC platform: "Our hTSC platform is not only the earliest ethically sourced pluripotent stem cell source but also one of the most dynamic and versatile. This collaboration with Pluristyx underscores the transformative potential of hTSCs in the cell therapy industry."